

# NATIONAL QUALITY FORUM

## ESRD Submitted Measures

| Measure ID/ Title   | Measure Description   | Measure Steward                          |
|---|---|--|
| <b># 1418</b><br><b>Frequency of Adequacy Measurement for Pediatric Hemodialysis Patients</b> | Percentage of all pediatric (<18 years) patients receiving in-center Hemodialysis (HD) (irrespective of frequency of dialysis) with documented monthly adequacy measurements (spKt/V) or its components in the calendar month   | Centers for Medicare & Medicaid Services |
| <b># 1421</b><br><b>Method of Adequacy Measurement for Pediatric Hemodialysis Patients</b>    | Percentage of pediatric (<18 years old) in-center hemodialysis HD patients (irrespective of frequency of dialysis) for whom delivered HD dose was measured by spKt/V as calculated using UKM or Daugirdas II during the reporting period  | Centers for Medicare & Medicaid Services |
| <b># 1423</b><br><b>Minimum spKt/V for Pediatric Hemodialysis Patients</b>                    | Percentage of all pediatric (<18 years old) in-center HD patients who have been on hemodialysis for 90 days or more and dialyzing 3 or 4 times weekly whose delivered dose of hemodialysis (calculated from the last measurements of the month using the Urea Kinetic Modeling (UKM) or Daugirdas II formula) was a spKt/V $\geq 1.2$ | Centers for Medicare & Medicaid Services |
| <b># 1424</b><br><b>Monthly Hemoglobin Measurement for Pediatric Patients</b>                 | Percentage of all pediatric (<18 years) hemodialysis and peritoneal dialysis patients who have monthly measures for hemoglobin  | Centers for Medicare & Medicaid Services |
| <b># 1425</b><br><b>Measurement of nPCR for Pediatric Hemodialysis Patients</b>               | Percentage of pediatric (<18 years old) in-center HD patients (irrespective of frequency of dialysis) with documented monthly nPCR measurements   | Centers for Medicare & Medicaid Services |
| <b># 1426</b><br><b>Assessment of Iron Stores</b>   | Percentage of all adult ( $\geq 18$ years old) dialysis patients for whom serum ferritin and transferrin saturation (TSAT) percentage are measured simultaneously at least once during the three-month study period   | Centers for Medicare & Medicaid Services |
| <b># 1427</b><br><b>Adult Dialysis Patients - Serum Phosphorus &gt;6 mg/dl</b>                | Proportion of patients with 3-month rolling average of serum phosphorus > 6 mg/dl   | Genzyme Corporation                      |

| Measure ID/ Title   | Measure Description   | Measure Steward                          |
|---|---|--|
| <b># 1428</b><br><b>Use of Iron Therapy When Indicated</b>                | Percentage of all adult ( $\geq 18$ years old) dialysis patients with a serum ferritin $< 100$ ng/mL and a transferrin saturation (TSAT) $< 50\%$ on at least one simultaneous measurement who received intravenous (IV) iron in the following three months   | Centers for Medicare & Medicaid Services |
| <b># 1429</b><br><b>Avoidance of Iron Therapy in Iron Overload</b>        | Percentage of all adult ( $\geq 18$ years old) dialysis patients with a serum ferritin $\geq 1200$ ng/mL or a transferrin saturation (TSAT) $\geq 50\%$ on at least one simultaneous measurement during the three-month study period who did not receive IV iron in the following three months  | Centers for Medicare & Medicaid Services |
| <b># 1430</b><br><b>Lower Limit of Hemoglobin for Pediatric Patients</b>  | Percentage of pediatric ( $< 18$ years old) hemodialysis and peritoneal dialysis patients, with ESRD $\geq 3$ months, who have a mean hemoglobin $< 10$ g/dL for a 3 month reporting period, irrespective of Erythropoietin Stimulating Agent (ESA) use. The hemoglobin value reported at the end of each reporting month (end-of-month hemoglobin) is used for the calculation | Centers for Medicare & Medicaid Services |
| <b># 1431</b><br><b>Measurement of Iron Stores for Pediatric Patients</b> | Percentage of all pediatric ( $< 18$ years old) hemodialysis and peritoneal dialysis patients prescribed an ESA at any time during the study period or who have a Hb $< 11.0$ g/dL in at least one month of the study period for whom serum ferritin concentration and percent transferrin saturation (TSAT) are measured at least once in a three-month period                 | Centers for Medicare & Medicaid Services |
| <b># 1432</b><br><b>Dietary Sodium Reduction Advice</b>                   | The proportion of patients who have received formal advice on dietary sodium restriction by the renal dietician within the past 90 days   | Centers for Medicare & Medicaid Services |
| <b># 1433</b><br><b>Use of Iron Therapy for Pediatric Patients</b>        | Percentage of all pediatric ( $< 18$ years old) hemodialysis and peritoneal dialysis patients with hemoglobin $< 11.0$ g/dL and in whom simultaneous values of serum ferritin concentration was $< 100$ ng/ml and transferrin saturation (TSAT) $< 20\%$ who received IV iron or were prescribed oral iron within the following three months                                    | Centers for Medicare & Medicaid Services |
| <b># 1434</b><br><b>Sodium Profiling Practice for Hemodialysis</b>        | Proportion of patients who were not prescribed sodium profiling in the reporting month  | Centers for Medicare & Medicaid Services |
| <b># 1435</b><br><b>Restriction of Dialysate Sodium</b>                   | Proportion of patients who were prescribed a dialysate sodium concentration $\leq 138$ mEq/L for all sessions in the reporting month  | Centers for Medicare & Medicaid Services |

| Measure ID/ Title  | Measure Description  | Measure Steward                          |
|--|--|--|
| # 1436<br><b>IV Antibiotic Therapy (rate)</b>  | Six-month rolling average rate of initiating IV antibiotic prescription therapy for newly suspected infection among adult chronic hemodialysis (HD) patients (Express as: rate per 1000 HD patient days)                                   | Centers for Medicare & Medicaid Services |
| # 1437<br><b>Utilization of Dialysis Duration of Four Hours or Longer for Patients New to Dialysis</b> | The proportion of patients new to dialysis whose prescribed dialysis session length is at least 240 minutes  | Centers for Medicare & Medicaid Services |
| # 1438<br><b>Periodic Assessment of Post-Dialysis Weight by Nephrologists</b>                          | The proportion of patients who have documentation of receiving a new post-dialysis weight prescription from a nephrologist in the reporting month  | Centers for Medicare & Medicaid Services |
| # 1439<br><b>Utilization of High Ultrafiltration Rate for Fluid Removal</b>                            | Proportion of patients who did not receive an ultrafiltration rate $\geq 15$ ml/kg/hr in the reporting month   | Centers for Medicare & Medicaid Services |
| # 1447<br><b>Clinically Confirmed Infection (percentage)</b>   | Six-month rolling average prevalence of clinically confirmed infection among HD patients prescribed IV antibiotics (Express as: percentage)  | Centers for Medicare & Medicaid Services |
| # 1449<br><b>Unavailable Blood Culture Results (percentage)</b>  | Six-month rolling average prevalence of “unavailable” blood culture results for adult chronic hemodialysis (HD) patients prescribed IV antibiotics (Express as: percentage)  | Centers for Medicare & Medicaid Services |
| # 1450<br><b>Unavailable Clinical Confirmation (percentage)</b>  | Six-month rolling average prevalence of “unavailable” information regarding clinical confirmation of infection among adult chronic hemodialysis (HD) patients with new IV antibiotic prescription (Express as: percentage)                 | Centers for Medicare & Medicaid Services |
| # 1452<br><b>Fistula-Related Bacteremia (rate)</b>   | Six-month rolling average rate for access-related bacteremia with IV antibiotic therapy, among adult chronic hemodialysis (HD) patients using an arteriovenous fistula for hemodialysis access (Express as: rate per 1000 HD fistula days) | Centers for Medicare & Medicaid Services |
| # 1453<br><b>Clinically Confirmed Infection (rate)</b>   | Six-month rolling average rate of clinically confirmed infection with IV antibiotic therapy among adult chronic HD patients (Express as: rate per 1000 HD patient days)  | Centers for Medicare & Medicaid Services |

| Measure ID/ Title   | Measure Description  | Measure Steward                            |
|---|--|--|
| # 1454<br>Proportion of Patients with Hypercalcemia                               | Proportion of patients with 3-month rolling average of total uncorrected serum calcium >10.2 mg/dL   | Centers for Medicare & Medicaid Services   |
| # 1455<br>Graft-Related Bacteremia (rate)   | Six-month rolling average rate for access-related bacteremia with IV antibiotic therapy, among adult chronic hemodialysis (HD) patients using an arteriovenous graft for hemodialysis access (Express as: rate per 1000 HD graft days) | Centers for Medicare & Medicaid Services   |
| # 1456<br>Bacteremia (rate)   | Six-month rolling average rate of bacteremia with IV antibiotic therapy, among adult chronic HD patients (Express as: rate per 1000 HD patient days)   | Centers for Medicare & Medicaid Services   |
| # 1457<br>Catheter-Related Bacteremia (rate)                                      | Six-month rolling average rate for access-related bacteremia with IV antibiotic therapy, among adult chronic hemodialysis (HD) patients using a catheter for HD access (Express as: rate per 1000 HD catheter days)                    | Centers for Medicare & Medicaid Services   |
| # 1458<br>Bacteremia (percentage)   | Six-month rolling average prevalence of bacteremia among adult chronic HD patients prescribed IV antibiotics (Express as: percentage)  | Centers for Medicare & Medicaid Services   |
| # 1459<br>Fistula-Related Infection (rate)  | Six-month rolling average rate for access-related infection with IV antibiotic therapy, among adult chronic hemodialysis (HD) patients using an arteriovenous fistula for HD access (Express as: rate per 1000 HD fistula days)        | Centers for Medicare & Medicaid Services   |
| # 1460<br>National Healthcare Safety Network (NHSN) Bloodstream Infection Measure | Number of hemodialysis outpatients with positive blood cultures per 100 hemodialysis patient-months  | Centers for Disease Control and Prevention |
| # 1461<br>Proportion of Patients with Hypophosphatemia                            | Proportion of patients with 3-month rolling average of serum phosphorus < 2.5 mg/dL  | Centers for Medicare & Medicaid Services   |
| # 1462<br>Vascular Access-Related Infection (rate)                                | Six-month rolling average rate of hemodialysis vascular access-related infection with IV antibiotic therapy among adult chronic HD patients (Express as: rate per 1000 HD patient days)  | Centers for Medicare & Medicaid Services   |

This information is for personal and noncommercial use only. You may not modify, reformat, copy, display, distribute, transmit, publish, license, create derivative works from, transfer or sell any information, products or services obtained from this document.

| <b>Measure ID/ Title</b>  | <b>Measure Description</b>  | <b>Measure Steward</b>                   |
|---|---|--|
| <b># 1463<br/>Standardized Hospitalization Ratio for Admissions</b> | Risk-adjusted standardized hospitalization ratio for admissions for dialysis facility patients  | Centers for Medicare & Medicaid Services |
| <b># 1464<br/>Standardized Hospitalization Ratio for Days</b>       | Risk-adjusted standardized hospitalization ratio for days for dialysis facility patients  | Centers for Medicare & Medicaid Services |
| <b># 1465<br/>Vascular Access-Related Infection (percentage)</b>    | Six-month rolling average prevalence of hemodialysis access-related infection among adult chronic HD patients with a clinically confirmed infection and prescribed IV antibiotics (Express as: percentage)                  | Centers for Medicare & Medicaid Services |
| <b># 1466<br/>Vascular Access-Related Bacteremia (percentage)</b>   | Six-month rolling average prevalence of bacteremia among adult chronic HD patients with a hemodialysis access-related infection and prescribed IV antibiotics (Express as: percentage)                                      | Centers for Medicare & Medicaid Services |
| <b># 1467<br/>Graft-Related Infection (rate)</b>                    | Six-month rolling average rate for access-related infection with IV antibiotic therapy, among adult chronic hemodialysis (HD) patients using an arteriovenous graft for HD access (Express as: rate per 1000 HD graft days) | Centers for Medicare & Medicaid Services |
| <b># 1468<br/>Catheter-Related Infection (percentage)</b>           | Six-month rolling average prevalence of hemodialysis catheter-related infection among adult chronic HD patients with a HD access-related infection and prescribed IV antibiotics (Express as: percentage)                   | Centers for Medicare & Medicaid Services |
| <b># 1469<br/>Catheter-Related Infection (rate)</b>                 | Six-month rolling average rate for access-related infection with IV antibiotic therapy, among adult chronic hemodialysis (HD) patients using a catheter for HD access (Express as: rate per 1000 HD catheter days)          | Centers for Medicare & Medicaid Services |
| <b># 1470<br/>Graft-Related Infection (percentage)</b>              | Six-month rolling average prevalence of hemodialysis arteriovenous graft-related infection among adult chronic HD patients with a HD access-related infection and prescribed IV antibiotics (Express as: percentage)        | Centers for Medicare & Medicaid Services |
| <b># 1471<br/>Fistula-Related Infection (percentage)</b>            | Six-month rolling average prevalence of hemodialysis (HD) arteriovenous fistula-related infection among adult chronic HD patients with a HD access-related infection and prescribed IV antibiotics (Express as: percentage) | Centers for Medicare & Medicaid Services |

| Measure ID/ Title   | Measure Description   | Measure Steward                            |
|---|---|--|
| <b># 1477</b><br><b>National Healthcare Safety Network (NHSN) Intravenous (IV) Antibiotic Start Measure</b>             | Monthly rate of outpatient intravenous antibiotic starts (initiation of a new antibiotic not in use in previous 21 days) per 100 patient months within outpatient dialysis unit. The 21 day rule is used to exclude counting antibiotics that are given for the same infection more than once | Centers for Disease Control and Prevention |
| <b># 1478</b><br><b>National Healthcare Safety Network (NHSN) Vascular Access-Related Bloodstream Infection Measure</b> | Number of hemodialysis outpatients with positive blood cultures and in whom the suspected source was reported as either the vascular access or unknown, per 100 hemodialysis patient-months   | Centers for Disease Control and Prevention |